H19 and Hepatic fibrosis: These studies suggest that EVs and cargo H19 delivery from cholangiocytes to other liver cells such as hepatocytes and HSCs are a critical step for pathogenesis of cholestatic liver injury, and H19 could be another therapeutic target for the treatment of liver fibrosis.